BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33589753)

  • 1. Two decades of targeted therapies in acute myeloid leukemia.
    Cucchi DGJ; Polak TB; Ossenkoppele GJ; Uyl-De Groot CA; Cloos J; Zweegman S; Janssen JJWM
    Leukemia; 2021 Mar; 35(3):651-660. PubMed ID: 33589753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision therapy for acute myeloid leukemia.
    Yang X; Wang J
    J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia.
    Click ZR; Seddon AN; Bae YR; Fisher JD; Ogunniyi A
    Pharmacotherapy; 2018 Nov; 38(11):1143-1154. PubMed ID: 30220082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.
    Short NJ; Konopleva M; Kadia TM; Borthakur G; Ravandi F; DiNardo CD; Daver N
    Cancer Discov; 2020 Apr; 10(4):506-525. PubMed ID: 32014868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drug approvals in acute myeloid leukemia: an unprecedented paradigm shift.
    Kopmar NE; Estey EH
    Clin Adv Hematol Oncol; 2019 Oct; 17(10):569-575. PubMed ID: 31730583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.
    Miyamoto K; Minami Y
    Int J Clin Oncol; 2019 Aug; 24(8):893-898. PubMed ID: 31111287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecularly targeted therapy in acute myeloid leukemia.
    Gill H; Leung AY; Kwong YL
    Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
    Naqvi K; Konopleva M; Ravandi F
    Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapeutics in acute myeloid leukemia.
    Sweet K; Lancet JE
    Curr Hematol Malig Rep; 2014 Jun; 9(2):109-17. PubMed ID: 24633743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatment for acute myelogenous leukemia.
    DiNardo CD; Cortes JE
    Expert Opin Pharmacother; 2015 Jan; 16(1):95-106. PubMed ID: 25480777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine.
    Lam SS; He AB; Leung AY
    Blood Rev; 2017 Nov; 31(6):418-425. PubMed ID: 28797519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia.
    Yilmaz M; Daver N
    Drugs; 2019 Jul; 79(11):1177-1186. PubMed ID: 31222627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutting Edge Molecular Therapy for Acute Myeloid Leukemia.
    Miyamoto K; Minami Y
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapies for AML: a round-up for clinicians.
    Swaminathan M; Wang ES
    Expert Rev Clin Pharmacol; 2020 Dec; 13(12):1389-1400. PubMed ID: 33412978
    [No Abstract]   [Full Text] [Related]  

  • 17. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
    Bewersdorf JP; Stahl M; Zeidan AM
    Leuk Lymphoma; 2019 Jun; 60(6):1354-1369. PubMed ID: 30652518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop.
    Wang ES; Baron J
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):57-66. PubMed ID: 33275692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and emerging therapies for acute myeloid leukaemia.
    Davis JR; Benjamin DJ; Jonas BA
    J Investig Med; 2018 Dec; 66(8):1088-1095. PubMed ID: 30127098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating newer agents in the treatment of acute myeloid leukemia.
    Raj RV; Abedin SM; Atallah E
    Leuk Res; 2018 Nov; 74():113-120. PubMed ID: 30401522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.